Firefly Neuroscience, Inc. is a US-listed company in the health care technology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Firefly Neuroscience, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.
Firefly Neuroscience, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Firefly Neuroscience has little or no product revenue yet; it used $7m of cash in the twelve months to June 2026. It passes 2 of our 2 financial-health checks.
Our model value for Firefly Neuroscience is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Firefly Neuroscience, Inc.'s trailing-twelve-month revenue grew 320.3% year on year, with a free-cash-flow margin of -388.6%. Where it stands out: revenue growth of 320.3% ranks 1 of 23 health care technology companies we cover. Where it lags: change in growth rate of -719.2pp ranks 23 of 23 health care technology companies we cover.
Current signal Revenue growth decelerating: TTM revenue growth slowed to 320.3% (-719.2pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Firefly Neuroscience, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11%: the 10-year Treasury yield (4.9%) plus a beta of 1.34 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.1 ~$0.1–$0.5 | Left out: out of range vs price (0.05x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Firefly Neuroscience, Inc. with Health Care Technology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $3.90 | $3.60 | $12.60 | $4.20 | $3.90 | $43.50 | $148.50 | $14.40 | $5.07 | $2.65 | $0.88 | $0.99 |
| Market value | $18m | $16m | $58m | $19m | $17m | $210m | $747m | $102m | $66m | $35m | $11m | $16m |
| + Net debt (− = net cash) | −$2m | −$2m | −$3m | −$2m | −$1m | −$1m | −$5m | −$306081 | −$181995 | $0 | −$3m | −$9m |
| Enterprise value | $15m | $14m | $56m | $17m | $16m | $208m | $742m | $102m | $65m | $35m | $8m | $7m |
| Multiples | ||||||||||||
| Price / sales | 2.8x | 2.4x | 5.5x | 2.1x | 1.7x | 15.1x | 49.7x | 8.5x | 131.7x | n/m | 9.6x | 8.8x |
| Price / earnings | n/m | — | n/m | — | — | n/m | — | — | — | — | — | — |
| Price / free cash flow | — | — | 69.9x | — | — | n/m | — | — | — | — | — | — |
| EV / EBITDA | 157.9x | — | n/m | — | — | n/m | — | — | — | — | — | — |
Weak moat
How hard Firefly Neuroscience's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median 3.8% of total assets over 10 years.
Gross margin has been a median 23.6%, moving by 22.1 percentage points (standard deviation) across 10 years.
Operating margin has been a median -17.1%; its worst year was -7131.2%.
Free cash flow was positive in 3 of 10 years, at a median -23.2% of revenue.
The diluted share count rose 4071.7% over five years; stock-based pay has been a median 5.4% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (23 before it).
No analyst estimates are published for Firefly Neuroscience, Inc.: too few analysts cover it.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| AIFF | +241% | −90% | −65% | −48% | −67% | +13% |
| Industry peers (median) | −14% | −60% | −16% | −8% | −27% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| AIFF | 58% | 17% | 42% | 42% | 25% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| AIFF | −34% | −93% | −90% | −78% | −94% | −70% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from March 28, 2022 to February 23, 2026. Getting back needed a 27322% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| December 4, 2024 | −1.6% | +0.5% | −3.9% | −16.7% |
| November 15, 2024 | −6.0% | −0.9% | −6.0% | −13.5% |
| November 21, 2022 | −25.0% | +1.0% | −31.6% | −47.4% |
| August 15, 2022 | +6.5% | +0.6% | +8.9% | −6.5% |
| May 23, 2022 | −18.9% | +1.1% | −8.9% | −38.2% |
| April 18, 2022 | +6.4% | +1.7% | +2.7% | −34.5% |
| November 3, 2021 | −10.8% | +1.1% | −17.0% | −10.0% |
| August 18, 2021 | −4.2% | −0.9% | +3.4% | +14.6% |
| May 18, 2021 | −4.2% | −1.1% | +5.9% | +29.7% |
| February 17, 2021 | +23.2% | −0.4% | +8.9% | +52.6% |
| November 16, 2020 | +29.2% | +0.7% | +53.8% | +83.1% |
| August 18, 2020 | +21.2% | −0.2% | +63.6% | +100.0% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $6.6M |
| FY23 Q4 | $4.2M |
| FY24 Q1 | $2.1M |
| FY24 Q2 | $64K |
| FY24 Q3 | $74K |
| FY24 Q4 | $108K |
| FY25 Q1 | $139K |
| FY25 Q2 | $428K |
| FY25 Q3 | $783K |
| FY25 Q4 | $1.1M |
| FY26 Q1 | $1.6M |
| FY26 Q2 | $1.8M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | -43.2% |
| FY23 Q4 | -63.1% |
| FY24 Q1 | -80.4% |
| FY24 Q2 | -99.3% |
| FY24 Q3 | -98.9% |
| FY24 Q4 | -97.4% |
| FY25 Q1 | -93.3% |
| FY25 Q2 | 568.8% |
| FY25 Q3 | 958.1% |
| FY25 Q4 | 957.4% |
| FY26 Q1 | 1039.6% |
| FY26 Q2 | 320.3% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -32.1% |
| FY23 Q4 | -63.3% |
| FY24 Q1 | -135.3% |
| FY24 Q2 | -7131.3% |
| FY24 Q3 | -11060.8% |
| FY24 Q4 | -9309.3% |
| FY25 Q1 | -7933.8% |
| FY25 Q2 | -2664.3% |
| FY25 Q3 | -1250.4% |
| FY25 Q4 | -775.5% |
| FY26 Q1 | -555.6% |
| FY26 Q2 | -508.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | -43.5% |
| FY23 Q4 | -51.4% |
| FY24 Q1 | -83.1% |
| FY24 Q2 | -3807.0% |
| FY24 Q3 | -7360.8% |
| FY24 Q4 | -5699.1% |
| FY25 Q1 | -5285.6% |
| FY25 Q2 | -2018.2% |
| FY25 Q3 | -971.5% |
| FY25 Q4 | -717.5% |
| FY26 Q1 | -481.8% |
| FY26 Q2 | -388.6% |
| Fiscal year | 2010 Dec 2010 | 2011 Dec 2011 | 2012 Dec 2012 | 2013 Dec 2013 | 2014 Dec 2014 | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||||||||
| Revenue | 7 | 8 | 7 | 7 | 6 | 6 | 7 | 11 | 9 | 10 | 14 | 15 | 12 | 0 | 0 | 1 | 2 |
| Gross profit | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 4 | 3 | 3 | 0 | 1 | 1 |
| EBITDA | 0 | 0 | 0 | −0 | −0 | 0 | −1 | 0 | −0 | −1 | 0 | −2 | −5 | −3 | −10 | −9 | −9 |
| Operating income | 0 | 0 | 0 | −0 | −0 | 0 | −1 | 0 | −0 | −1 | 0 | −3 | −5 | −3 | −10 | −9 | −9 |
| Net income | 0 | 0 | 0 | −0 | −0 | 0 | −1 | 0 | −0 | −1 | 0 | −1 | −18 | −3 | −10 | −20 | −9 |
| Diluted EPS | $0.03 | $0.00 | $0.00 | −$0.00 | $0.00 | $0.00 | −$0.01 | $0.01 | $0.00 | −$0.01 | $0.01 | −$0.23 | — | — | — | — | −$0.57 |
| Growth (year on year) | |||||||||||||||||
| Revenue | — | +14.0% | −9.8% | +6.0% | −22.7% | +7.5% | +8.3% | +58.1% | −16.0% | +13.8% | +36.8% | +8.1% | −20.0% | −95.9% | −78.3% | +957.4% | +320.3% |
| EBITDA | — | +5.3% | −27.7% | — | — | — | — | — | −120.6% | — | — | −663.9% | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | −126.2% | — | — | −737.9% | — | — | — | — | — |
| Net income | — | +4.7% | — | — | — | — | — | — | −120.7% | — | — | −373.7% | — | — | — | — | — |
| Diluted EPS | — | −90.0% | — | — | — | — | — | — | −100.0% | — | — | <−999% | — | — | — | — | — |
| Margins | |||||||||||||||||
| Gross margin | 34.8% | 31.2% | 34.2% | 30.2% | 41.3% | 38.2% | 27.1% | 22.7% | 24.0% | 13.8% | 15.9% | 24.1% | 23.8% | — | 100.0% | 56.5% | 44.6% |
| EBITDA margin | 2.3% | 2.2% | 1.7% | −0.6% | −0.1% | 1.6% | −8.0% | 2.4% | −0.6% | −7.1% | 3.0% | −15.9% | −43.2% | −618.1% | <−999% | −760.4% | −501.6% |
| Operating margin | 2.0% | 1.9% | 1.3% | −0.9% | −0.7% | 1.1% | −8.4% | 2.2% | −0.7% | −7.2% | 3.0% | −17.5% | −45.1% | −618.1% | <−999% | −775.5% | −508.1% |
| Net margin | 2.1% | 2.0% | 1.4% | −0.8% | −0.5% | 1.3% | −8.2% | 2.3% | −0.6% | −7.1% | 3.0% | −7.5% | −147.7% | −522.7% | <−999% | <−999% | −506.2% |
| Free-cash-flow margin | 7.4% | −8.9% | 18.9% | −3.4% | 1.5% | −4.6% | −4.0% | 7.8% | −8.6% | −9.1% | 2.6% | −5.4% | −54.5% | −436.1% | <−999% | −717.5% | −388.6% |
| Cash flow | |||||||||||||||||
| Cash from operations | 1 | −1 | 1 | −0 | 0 | −0 | −0 | 1 | −1 | −1 | 0 | −1 | −6 | −2 | −6 | −8 | −7 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | 1 | −1 | 1 | −0 | 0 | −0 | −0 | 1 | −1 | −1 | 0 | −1 | −7 | −2 | −6 | −8 | −7 |
| Stock-based pay | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 3 | 1 | 1 |
| Free cash flow after stock pay | 0 | −1 | 1 | −0 | 0 | −0 | −0 | 1 | −1 | −1 | 0 | −3 | −8 | −2 | −9 | −9 | −8 |
| Balance sheet | |||||||||||||||||
| Cash | 2 | 1 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 1 | 2 | 5 | 1 | 1 | — | 3 | 9 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Net debt (negative = net cash) | −2 | −1 | −3 | −2 | −2 | −2 | −2 | −3 | −2 | −1 | −1 | −5 | −0 | −0 | — | −3 | −9 |
| Diluted shares | 4m | 4m | 4m | 4m | 4m | 5m | 4m | 5m | 4m | 4m | 5m | 5m | 7m | 13m | 13m | 12m | 16m |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | −4 | −3 | −2 | −2 | −3 | −2 | −2 | −2 |
| Operating income | −4 | −3 | −2 | −2 | −3 | −3 | −2 | −2 |
| Net income | −4 | −4 | −13 | −2 | −3 | −2 | −2 | −2 |
| Diluted EPS | −$0.61 | — | — | — | −$0.20 | — | — | — |
| Growth (year on year) | ||||||||
| Revenue | +43.5% | +178.9% | +258.3% | +>999% | +>999% | +677.4% | +>999% | +71.9% |
| Margins | ||||||||
| Gross margin | 100.0% | 100.0% | 100.0% | 91.6% | 37.6% | 44.2% | 45.6% | 49.2% |
| EBITDA margin | <−999% | <−999% | <−999% | −543.1% | −682.0% | −594.4% | −405.2% | −382.1% |
| Operating margin | <−999% | <−999% | <−999% | −546.5% | −684.5% | −607.0% | −414.4% | −384.0% |
| Net margin | <−999% | <−999% | <−999% | −613.0% | −680.2% | −601.9% | −413.2% | −386.0% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | −799.3% | −383.5% | −438.1% | −401.6% | −340.5% |
| Cash flow | ||||||||
| Cash from operations | −3 | −1 | −3 | −2 | −1 | −2 | −2 | −2 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −3 | −1 | −3 | −2 | −1 | −2 | −2 | −2 |
| Stock-based pay | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow after stock pay | −5 | −1 | −3 | −2 | −2 | −2 | −2 | −2 |
| Last 12 months unless stated | AIFF | ONMD | WORX | MNDR | DRIO | HCTI | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $2m | $1m | $3m | $8m | $21m | $26m | $292m |
| Revenue growth, last 12 months | 320.3% | 216.5% | 3.1% | 1.2% | −22.6% | 116.4% | 8.8% |
| Revenue growth, 3-year average | −41.3% | — | −9.9% | — | −7.6% | −14.9% | 0.8% |
| Revenue growth, latest quarter | 71.9% | 88.4% | 3.4% | — | −3.6% | 158.4% | 7.4% |
| Gross margin | 44.6% | −68.8% | 44.7% | 21.2% | 58.2% | 21.5% | 58.6% |
| Operating margin | −508.1% | −695.7% | −20.1% | — | −151.6% | −57.4% | −12.5% |
| Operating margin, 3-year average | <−999% | <−999% | −36.9% | — | −213.6% | −40.6% | −18.8% |
| Net margin | −506.2% | −584.2% | −80.5% | −41.2% | −169.9% | −66.3% | −12.5% |
| Cash from operations / revenue | −388.6% | −472.3% | −25.5% | −19.7% | −120.7% | −62.4% | 9.7% |
| Free-cash-flow margin | −388.6% | −473.4% | −86.6% | −19.7% | −121.3% | −62.4% | 9.2% |
| Free-cash-flow margin, 3-year average | <−999% | −910.1% | — | — | −144.7% | −44.7% | 8.2% |
| Stock pay / revenue | 62.0% | 173.1% | 9.5% | 19.9% | 33.6% | 3.2% | 9.5% |
| Change in share count | 27.7% | 62.6% | 207.2% | 265.5% | 25.9% | — | 2.9% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 320.3% | 8.8% | 1 of 23 |
| Change in growth rate Growth | -719.2pp | -0.3pp | 23 of 23 |
| Gross margin Profitability | 44.6% | 58.2% | 11 of 14 |
| Operating margin Profitability | -508.1% | -6.6% | 21 of 22 |
| Net margin Profitability | -506.2% | -12.5% | 22 of 23 |
| Free-cash-flow margin Cash generation | -388.6% | 10.6% | 21 of 22 |
| Stock pay as % of revenue Cash generation | 62.0% | 9.7% | 21 of 22 |
| Days sales outstanding Balance sheet | 38 days | 58 days | 5 of 21 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Services | $814,000 | 71.3% | ▲ 1885.4% |
| Products | $111,000 | 9.7% | — |
| Subscriptions | $110,000 | 9.6% | — |
| Rentals | $74,000 | 6.5% | ▲ 10.4% |
| Other | $33,000 | 2.9% | — |
From Firefly Neuroscience, Inc.'s 10-K filed March 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Murchinson Ltd. | $786,500 | 650K | 41.3% | New |
| Blackrock, Inc. | $226,474 | 187K | 11.9% | ▲ 10.5% |
| Boothbay Fund Management, LLC | $216,288 | 179K | 11.4% | New |
| Geode Capital Management, LLC | $147,085 | 122K | 7.7% | ▼ 22.3% |
| Vanguard Capital Management LLC | $135,411 | 112K | 7.1% | 0.0% |
| Jane Street Group, LLC | $82,073 | 68K | 4.3% | ▼ 62.4% |
| UBS Group AG | $71,534 | 59K | 3.8% | ▼ 55.3% |
| Vanguard Fiduciary Trust Co | $61,702 | 51K | 3.2% | 0.0% |
| State Street Corp | $56,022 | 46K | 2.9% | 0.0% |
| Northern Trust Corp | $40,528 | 33K | 2.1% | ▲ 112.5% |
| Virtu Financial LLC | $32,000 | 27K | 1.7% | New |
| Squarepoint Ops LLC | $17,291 | 14K | 0.9% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Firefly Neuroscience, Inc.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around March 3, 2025 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
